Shibata Y, Matsumura A, Yoshida F, Yamamoto T, Nakai K, Nose T, Sakata I, Nakajima S
Department of Neurosurgery, University of Tsukuba, Ibaraki, Japan.
Cancer Lett. 1998 Jul 3;129(1):77-85. doi: 10.1016/s0304-3835(98)00086-x.
We used a two-color analysis system to assess the porphyrin uptake and DNA content in four established cell lines of glioma employing flow cytometry (FCM). The FCM study revealed porphyrin uptake in all cells, regardless of the phase of the cell cycle they were in. However, those in the G0/G1 phase showed moderate uptake of porphyrin and those in the G2/M phase showed a higher uptake. These results indicated the advantage of using porphyrin as the carrier of tumor targeting agents as a therapeutic strategy for malignant tumors.
我们使用双色分析系统，通过流式细胞术（FCM）评估四种已建立的胶质瘤细胞系中的卟啉摄取和DNA含量。FCM研究显示，所有细胞均摄取了卟啉，无论它们处于细胞周期的哪个阶段。然而，处于G0/G1期的细胞对卟啉的摄取适中，而处于G2/M期的细胞摄取量更高。这些结果表明，将卟啉用作肿瘤靶向剂的载体作为恶性肿瘤的治疗策略具有优势。
